Shares of Vericel Corporation (NASDAQ:VCEL – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $62.00.
Several equities analysts recently commented on the stock. BTIG Research reaffirmed a “neutral” rating on shares of Vericel in a research note on Wednesday. Truist Financial boosted their price objective on shares of Vericel from $52.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday, July 30th. TD Cowen raised their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th.
Read Our Latest Analysis on VCEL
Vericel Stock Performance
Shares of VCEL stock opened at $58.26 on Friday. The company has a market cap of $2.97 billion, a P/E ratio of 91.03 and a beta of 1.08. The stock has a 50 day simple moving average of $44.31 and a two-hundred day simple moving average of $39.84. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $59.75.
Vericel (NASDAQ:VCEL – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The firm had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The business’s revenue was up 26.5% on a year-over-year basis. On average, research analysts predict that Vericel will post 0.78 earnings per share for the current year.
Insider Buying and Selling
In other news, CFO Joseph Mara, Jr. sold 25,000 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $58.26, for a total transaction of $1,456,500.00. Following the sale, the chief financial officer directly owned 16,186 shares in the company, valued at $942,996.36. This trade represents a 60.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sean Flynn sold 15,000 shares of Vericel stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total transaction of $778,800.00. Following the completion of the sale, the insider owned 1,990 shares in the company, valued at approximately $103,320.80. This represents a 88.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 49,008 shares of company stock worth $2,701,078. Corporate insiders own 7.60% of the company’s stock.
Institutional Investors Weigh In On Vericel
Hedge funds and other institutional investors have recently bought and sold shares of the company. MCF Advisors LLC lifted its holdings in shares of Vericel by 293.0% during the second quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of Vericel in the second quarter worth approximately $36,000. Hantz Financial Services Inc. boosted its position in Vericel by 24.8% during the third quarter. Hantz Financial Services Inc. now owns 1,194 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 237 shares during the last quarter. Allworth Financial LP purchased a new stake in Vericel in the 2nd quarter valued at $60,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Vericel during the 2nd quarter worth approximately $72,000.
About Vericel
Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.
Featured Stories
- Five stocks we like better than Vericel
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
